ScoreWhy is Assembly Biosciences, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -14.80% and Operating profit at 3.01% over the last 5 years
2
With a growth in Net Sales of 293.63%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 7 consecutive quarters
- NET PROFIT(HY) Higher at USD -19.39 MM
- ROCE(HY) Highest at -36.94%
- NET SALES(Q) Highest at USD 10.79 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 152.75%, its profits have risen by 5.5%
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 17.89% over the previous quarter and currently hold 32.96% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
5
Market Beating Performance
- The stock has generated a return of 152.75% in the last 1 year, much higher than market (S&P 500) returns of 14.90%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Assembly Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Assembly Biosciences, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Assembly Biosciences, Inc.
152.75%
1.37
63.55%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-14.80%
EBIT Growth (5y)
3.01%
EBIT to Interest (avg)
-68.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.34
Sales to Capital Employed (avg)
0.77
Tax Ratio
0.83%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
25.62%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.49
EV to EBIT
-5.12
EV to EBITDA
-5.14
EV to Capital Employed
-4.51
EV to Sales
5.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-21.10%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
NET PROFIT(HY)
Higher at USD -19.39 MM
ROCE(HY)
Highest at -36.94%
NET SALES(Q)
Highest at USD 10.79 MM
RAW MATERIAL COST(Y)
Fallen by -0.18% (YoY
OPERATING PROFIT MARGIN(Q)
Highest at -100.57 %
EPS(Q)
Highest at USD -0.72
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Assembly Biosciences, Inc.
Net Sales
Highest at USD 10.79 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -19.39 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Sales
At USD 10.79 MM has Grown at 29.8%
over average net sales of the previous four periods of USD 8.31 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -100.57 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD -0.72
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -0.18% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
